method used is known to potentially generate artefact of the PCR. In our situation, we still believe that normal peripheral blood cells harbouring a JAK2V617F mutation do really exist, as the detection of a mutated allele was obtained with great reproducibility in several genomic DNA and cDNA preparations for each of our healthy positive controls. Furthermore, a mutated sequence was recurrently observed in two of these individuals. Our ability to get a mutated sequence despite a very low level of JAK2V617F-mutated alleles was due to the use of locked nucleic acid (LNA) oligonucleotide that limited the amplification of the wild-type JAK2 sequence and allowed thus to enrich sufficiently the PCR tube with mutated amplicons.
''The JAK2 V617F mutation is detectable in granulocyte populations at greater than two copies per cell among individuals with myeloproliferative disorders'', by El Housni et al. Leukemia (2007) 21, 817-818. doi:10.1038/sj.leu.2404569; published online 1 February 2007 In our recent letter to Leukemia, 1 we reported that in lieu of a definitive negative control, or the availability of an alternative 'gold standard' methodology to verify the accuracy of our quantitative assay for the JAK2 V617F mutation, we have used healthy controls as a surrogate to assess assay specificity, and also to establish a clinically useful range for supporting a diagnosis of myeloproliferative disorder.
We consider that amplification of small numbers of mutant JAK2 copies in normals could represent either mis-priming, or the presence of 3'-shortened mutation-specific primers (as it is only the very 3'-end base that confers specificity, and 3'-shortened primers will amplify from both wild type and mutant DNA). The primers in our assay were high-performance liquid chromatography (HPLC)-purified and we avoided freeze thawing. However, any reductions in the integrity and quality of the oligonucleotides could potentially contribute to non-specific amplification. Our assumption that low-level amplification of the JAK2 V617F sequence in healthy controls may represent artefact of the polymerase chain reaction (PCR) reaction, is also based on a previous publication, 2 where the authors demonstrated that the specificity of their assay to quantify donor and recipient hemopoietic cells by realtime-PCR of single nucleotide polymorphisms required a cutoff level for the crossing threshold (Ct) of 35 to exclude amplification of the negative allele. Similarly, we did not know whether amplification in healthy controls and in lymphocyte DNA after 36 cycles in our assay represented non-specific amplification of the wild-type JAK2 allele (or granulocyte contamination in the case of DNA from the lymphocyte fraction).
The assessment of non-specific amplification requires the availability of a true negative control. DNA for this purpose may potentially be sourced from clonal populations of cells (that are homogeneously wild type for the JAK2 allele). We adopted an alternative approach to testing assay specificity by serially diluting DNA from a healthy control sample in water and also in DNA from another control sample.
3 Fluorescent detection of a PCR product occurred after 36 cycles for all samples with DNA. However, we observed a poor relationship between the dilution factor and measures of mutational load, consistent with amplification being non-specific.
Our experience has certainly generated an enthusiasm to participate in quality assurance initiatives with groups such as Dr Sidon's et al., 4 where concordance of results for samples exchanged between sites represents the fundamental first step to deriving a meaningful clinical range for normal and disease measurements. 3 Hammond E, Shaw K, Carnley B, P'ng S, James I, Herrmann R. Quantitative determination of JAK2 V617F by TaqMan: an absolute measure of averaged copies per cell that may be associated with the different types of myeloproliferative disorders. J of Mol Diagnostics, (in press). We thank Hammond et al. for having provided technical arguments explaining why they consider the finding of mutant JAK2 copies in normal granulocytes as polymerase chain reaction (PCR) artefacts. 1 According to the technical details given, we can understand why the discrimination between the wild-type and mutant JAK2 allele is not absolute as it is only based on the specificity of the 3 0 -end base of a primer. Our methodology is clearly different. 2 Furthermore, the positive results that we obtained were highly reproducible: in patients who showed to be initially positive, the mutation was recurrently found in repeated PCR performed on both genomic DNA and cDNA preparations. Moreover, some of the positive PCR results were confirmed by sequencing. Therefore, we have good reasons to consider that the JAK2V617F mutation found in some of our normal patients is not a PCR artefact.
